Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Total Liabilities
Everything the company owes to creditors and other parties.
Fulgent Genetics, Inc.NASDAQ: FLGT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 35.2% from a year ago
Total liabilities stood at $112.22M at the end of Q1 FY2026, up 35.2% from a year earlier and up 5.1% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Total liabilities amounted to 9.7% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +35.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 106.81M USD
- Year-over-year change
- +17.6%
- 4-year CAGR
- -1.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.81M | +17.6% |
| FY2024 | 2024-12-31 | 90.81M | -11.0% |
| FY2023 | 2023-12-31 | 102.04M | -12.2% |
| FY2022 | 2022-12-31 | 116.18M | +3.0% |
| FY2021 | 2021-12-31 | 112.84M | — |
Total Liabilities vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's Mar 2026 total liabilities of $112.22M is the 7th highest of the 8 companies compared; the peer median is $336.3M.
- Its year-over-year change of +35.2% is the 2nd highest of 8, against a peer median of +27.1%.
- Total liabilities amounts to 9.7% of total assets for FLGT, versus a peer median of 41.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.16B | +32.5% | +10.9% | 114.6% | |
| Jun 2026 | $836M | +63.6% | +4.9% | 31.5% | |
| Jun 2026 | $565.65M | +4.8% | -11.0% | 41.8% | |
| Mar 2026 | $336.3M | +11.7% | +2.7% | 49.9% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $237.27M | +27.1% | -3.5% | 49.3% |
BLLNBillionToOne, Inc. | Jun 2026 | $192.89M | +34.4% | — | 26.4% |
| Mar 2026 | $112.22M | +35.2% | -2.8% | 9.7% | |
| Mar 2026 | $70.63M | +7.1% | -0.7% | 21.7% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $336.3M | +27.1% | +1.0% | 41.8% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 164.89M | 79.51M | 97.47M | 55.14M | 50.19M |
| Short-term Investments | 285.61M | 446.73M | 326.68M | 202.96M | 285.88M |
| Net Receivables | 143.3M | 75.11M | 57.45M | 77.03M | 91.61M |
| Inventory | 12.21M | 4.28M | 5.83M | 8.38M | 10.6M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 611.96M | 627.87M | 507.85M | 353.57M | 550.49M |
| Property, Plant & Equipment (Net) | 62.29M | 81.35M | 83.46M | 105.55M | 112.55M |
| Goodwill | 50.9M | 143.03M | 22.06M | 22.06M | 25.08M |
| Intangible Assets | 35.91M | 150.64M | 143.05M | 134.98M | 133.28M |
| Long-term Investments | 507.01M | 339.03M | 444.01M | 570.35M | 369.27M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 10.65M | 44.12M | 34.9M | 33.46M | 22.86M |
| Total Non-current Assets | 666.76M | 758.18M | 727.48M | 866.39M | 663.04M |
| Total Assets | 1.28B | 1.39B | 1.24B | 1.22B | 1.21B |
| Account Payables | 20.49M | 23.09M | 15.36M | 18.36M | 18.65M |
| Short-term Debt | 21.28M | 20.64M | 1.18M | 412K | 476K |
| Tax Payables | 787K | 0 | 0 | 0 | 107.1M |
| Deferred Revenue | 34.38M | 14.09M | 25.57M | 29.84M | 31.78M |
| Other Current Liabilities | 10.68M | 5.3M | 6.42M | 9.89M | 10.46M |
| Total Current Liabilities | 105.31M | 88.11M | 73.02M | 72.9M | 84.97M |
| Long-term Debt | 0 | 3.37M | 2.96M | 2.49M | 1.96M |
| Deferred Tax Liabilities | 0 | 0 | 7.96M | 6.37M | 6.94M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.53M | 15.9M | 10.95M | 4.92M | 9.17M |
| Total Non-current Liabilities | 7.53M | 28.07M | 29.02M | 17.91M | 21.84M |
| Total Liabilities | 112.84M | 116.18M | 102.04M | 90.81M | 106.81M |
| Common Stock | 3K | 3K | 3K | 3K | 3K |
| Retained Earnings | 657.6M | 801M | 633.18M | 590.47M | 529.95M |
| Accumulated OCI | (759K) | (20.9M) | 1.21M | (368K) | 7.51M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 7.13M | 3.19M | (2.82M) | (4.07M) | (5.27M) |
| Total Equity | 1.17B | 1.27B | 1.13B | 1.13B | 1.11B |
| Total Debt | 21.28M | 38.94M | 15.25M | 8.47M | 7.68M |
| Net Debt | (143.61M) | (40.57M) | (82.22M) | (46.68M) | (42.52M) |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.